Cryoservice manager runs the extra mile for Cancer Research
David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London
David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.
‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.
‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’
Bryant raised £3,350 for Cancer Research and came 16th.
Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.
You may also like
Media
Siemens named Leader in IDC MarketScape assessment of life sciences R&D technology
The company has been recognised for its end-to-end digital capabilities, AI-enabled portfolio and open Smart Lab Ecosystem in IDC’s 2026 assessment of life sciences R&D technology providers, with case studies from GSK and AstraZeneca highlighting the potential of digital twins and process modelling to accelerate development and manufacturing
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows